Alimera Sciences (ALIM) Reports In-Line Q2 EPS

Alimera Sciences (NASDAQ: ALIM) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $10.75 million.

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance